Risedronate for dilated cardiomyopathy caused by a Troponin T gene change
Tests risedronate on heart function in adults with Troponin T K210 deletion cardiomyopathy.
Key facts
- Who runs it
- Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 5 people, planned
- Started
- 8 Apr 2025
- Planned end
- 31 Jul 2026
- Type of study
- Interventional
- Record updated
- 22 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with dilated cardiomyopathy (an enlarged, weakened heart muscle) caused by the K210 deletion in the Troponin T gene. It tests Risedronate 10 mg/day.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Dilated cardiomyopathy with a left ventricular ejection fraction (LVEF, how well the heart pumps) of 50% or less.
- Earlier treatment
- People must not have used other investigational drugs at the time of inclusion or in the 30 days before.
- Biomarker or test result
- K210 deletion mutation in the Troponin T gene.
Main reasons for not taking part
- Allergy to Risedronate or low blood calcium (hypocalcemia).
- Severe kidney failure (eGFR < 30 ml/min/1.73m2).
- Esophagus (food pipe) disorders that slow emptying, such as stenosis or achalasia, or Barrett's esophagus.
- Not able to stay upright for at least 30 minutes after taking the tablet.
- Current corticosteroid or chemotherapy treatment, or being pregnant or breastfeeding.
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Older than 18 years old
- Dilated cardiomyopathy due to K210 deletion mutation in the Troponin T gene
- LVEF ≤ 50%
- Patients who have given written informed consent
Who cannot take part
- Active treatment with corticosteroids or chemotherapy
- Use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion
- Hypersensitivity to Risedronate
- History of esophageal disorders, with delay in transit or esophageal emptying, due to example, stenosis or achalasia
- Severe renal failure (eGFR < 30 ml/min/1.73m2)
- Hypocalcemia
- Barrett's esophagus
- Inability to remain upright for at least 30 minutes after taking of the tablet
- Pregnant or breastfeeding women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To study whether the administration of Risedronate 10 mg/day in patients with dilated cardiomyopathy due to K210 deletion mutation in the Troponin T gene is associated with: A change in left ventricular function, measured by Echocardiogram
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion.
- Plain-language title
- Risedronate for dilated cardiomyopathy caused by a Troponin T gene changeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 22 November 2024